Yin Ming Biological Overseas Publicly issued shares to apply for the receipt of the reception of the Securities Regulatory Commission

On August 8, 2022, Guangzhou Yinming Biomedical Technology Co., Ltd. submitted the approval of the first public offering of shares (including ordinary shares, preferred shares such as ordinary shares, priority shares and other shares and stocks) to the China Securities Regulatory Commission International Association.Receive materials on August 8.

Picture source: International Department of China Securities Regulatory Commission

Yinming creatures are Chinese companies focusing on independent innovation and research and development of global competitive drugs.The company has a R & D team composed of a number of top scientists and experts.The main product pipelines of Yin Ming biology include ophthalmology, restructuring protein botox, tumor immunotherapy, and pet immune drugs. Most of them are breakthrough first-in-class innovative drugs, and the main products have entered the clinical stage.

As of now, due to the 4 rounds of financing, investors include Haisong Capital, Yifeng Capital, Huacheng Venture Capital, Jifeng Capital, Tiger Global Fund, Gao Rong Capital, Lingcheng Investment, Yixian E -commerce, Taixin Capital, and Capital, and Capital, and Capital, and Capital.Lighting speed China, Huajin Capital, Hengqin Jindu, Integrity Venture Capital, Western Angel Fund, Ganming Capital, etc.

- END -